Impact of preoperative docetaxel, cisplatin, and 5-fluorouracil (DCF) therapy on degree of malignant esophageal stenosis

Table 2 Clinical and histopathological response to preoperative FP or DCF therapy

	FP group (n = 50)	DCF group (n = 31)	P value
Overall response (RECIST)
CR	4 (8.0)	3 (9.7)
PR	26 (52.0)	18 (58.1)
SD	13 (26.0)	7 (22.6)
PD	7 (14.0)	3 (9.7)
Response rate (CR + PR)	30 (60.0)	21 (67.7)	0.483 ^a
Endoscopic response rate (CR + PR)	28 (54.9)	24 (77.4)	*0.0401^a
Histopathological response in surgically resected cases
Grade 0	6 (12.0)	7 (22.6)
Grade 1a	30 (60.0)	12 (38.7)
Grade 1b	4 (8.0)	2 (6.5)
Grade 2	8 (16.0)	8 (25.8)
Grade 3	2 (4.0)	2 (6.5)
Grade ≥ 2	10 (20.0)	10 (32.3)	0.214 ^a

FP, 5-fluorouracil and cisplatin; DCF, docetaxel, cisplatin, and 5-fluorouracil; RECIST, Response Evaluation Criteria in Solid Tumors; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease;
*p < 0.05
^a χ² test

ISSN: 1471-230X